Skip Navigation LinksHome > January 2003 - Volume 7 - Issue 1 > Demonstration of Her-2 Protein in Cervical Carcinomas
Journal of Lower Genital Tract Disease:
Original Articles

Demonstration of Her-2 Protein in Cervical Carcinomas

Heller, Debra S.1; Hameed, Meera1; Aisner, Seena1; Cracchiolo, Bernadette2; Skurnick, Joan3; Scott, Diana2; Settembre, Dana1

Collapse Box


Objective. Recently, an immunohistochemical test for her-2-neu has been approved by the Food and Drug Administration for evaluation of breast cancer patients who might benefit from treatment with Herceptin (HercepTest). This study was undertaken to evaluate the immunohistochemical staining patterns in cervical cancer and correlate with clinical parameters.

Materials and Methods. A total of 24 cases of invasive squamous cell carcinoma of the cervix were evaluated. Cases were stained using the HercepTest kit according to protocol. Results were graded from 0 to 3+, using the standards set for breast lesions.

Results. A total of 17 cases (70.8%) were negative, 3 cases (12.5%) showed 1+ staining, and 4 cases (16.7%) showed 2+ staining. No cases showed 3+ staining. Higher her-2 staining grade correlated strongly with vaginal margin status. A weak positive correlation was seen between her-2 staining and tumor stage. There was no correlation with tumor grade or histological lymph node status.

Conclusions. A subset of invasive squamous cell carcinomas of the cervix overexpress her-2 protein. Further studies are needed to correlate with clinical outcome and determine if overexpression of her-2 protein is a marker of cervical carcinoma aggressiveness.

©2003The American Society for Colposcopy and Cervical Pathology


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.